Independent fund research. Built on SEC filings.

How we research funds

ETF overlap

IBRN vs SBIO overlap: 24% of top holdings shared

Bottom line

How much do IBRN and SBIO overlap?

24% of their top holdings overlap by weight. 6 securities appear in both funds' top 25, making up 26.4% of IBRN's assets and 16.8% of SBIO's. They are substantially different portfolios, so owning both adds real diversification.

Updated Nov 22, 2026

Overlap at a glance

IBRNSBIO
Weight overlap (top 25)24%
Shared holdings6
Weight in shared holdings26.4%16.8%
Total positions7889
Expense ratio0.47%0.5%
Holdings as ofJul 31, 2026May 31, 2026

Source: SEC Form N-PORT (periods Jul 31, 2026 / May 31, 2026)

Holdings IBRN and SBIO have in common

Holding% of IBRN% of SBIOOverlap
Dianthus Therapeutics Inc5.34%2.64%2.64%
Xenon Pharmaceuticals Inc4.87%2.90%2.90%
Acadia Pharmaceuticals Inc.4.69%2.35%2.35%
Alkermes Public Limited Company4.60%4.48%4.48%
Denali Therapeutics Inc3.67%2.13%2.13%
Edgewise Therapeutics Inc3.23%2.33%2.33%

Source: SEC Form N-PORT (periods Jul 31, 2026 / May 31, 2026)

Free weekly newsletter

The Fund Letter

Get fee cuts and hikes, fund closures and mergers, and one plain-English idea to make your portfolio cheaper — every week.

Free. Unsubscribe anytime. We never sell your email.

What each fund holds that the other doesn't

Top-25 holdings that appear in only one of the two funds' top 25.

Only in IBRN

  1. BlackRock Funds III: BlackRock Cash Funds: Institutional; SL Agency Shares — 14.64%
  2. Praxis Precision Medicines Inc — 4.87%
  3. Arrowhead Pharmaceuticals, Inc. — 4.65%
  4. Scholar Rock Holding Corp — 4.29%
  5. Biogen Inc. — 4.18%
  6. Neurocrine Biosciences, Inc. — 4.09%
  7. argenx SE — 3.86%
  8. Ptc Therapeutics, Inc. — 3.85%
  9. Axsome Therapeutics, Inc. — 3.77%
  10. Dyne Therapeutics, Inc — 3.56%
  11. Supernus Pharmaceuticals, Inc. — 2.61%
  12. AxoGen, Inc. — 2.34%
  13. SK Biopharmaceuticals Co Ltd — 2.30%
  14. H. Lundbeck A/s — 1.84%
  15. Biohaven Ltd — 1.82%

Only in SBIO

  1. Kymera Therapeutics Inc — 4.23%
  2. Celcuity Inc — 3.92%
  3. Mirum Pharmaceuticals Inc — 3.90%
  4. Spyre Therapeutics Inc — 3.68%
  5. Cg Oncology Inc — 3.35%
  6. Apogee Therapeutics Inc — 2.93%
  7. Travere Therapeutics Inc — 2.77%
  8. Newamsterdam Pharma Co Nv — 2.47%
  9. Viking Therapeutics Inc — 2.41%
  10. Crinetics Pharmaceuticals Inc — 2.37%
  11. Oruka Therapeutics Inc — 1.81%
  12. Structure Therapeutics Inc — 1.78%
  13. Disc Medicine Inc — 1.69%
  14. Ideaya Biosciences Inc — 1.65%
  15. Vera Therapeutics Inc — 1.61%

Asset mix

Asset typeIBRNSBIO
Stocks95.5%100.0%
Cash & short-term funds14.8%—
Other4.4%—

Source: SEC Form N-PORT (periods Jul 31, 2026 / May 31, 2026)

Country mix

CountryIBRNSBIO
US85.2%80.2%
CA5.5%2.9%
IE5.0%4.5%
NL3.9%4.7%
KY—4.7%
KR2.4%—
SE2.4%—
CH1.8%0.8%

Source: SEC Form N-PORT (periods Jul 31, 2026 / May 31, 2026)

Check another pair

FAQ

How much do IBRN and SBIO overlap?
About 24% by weight. 6 securities appear in both funds' top 25 holdings; they make up 26.4% of IBRN's assets and 16.8% of SBIO's. They are substantially different portfolios, so owning both adds real diversification.
What stocks do IBRN and SBIO have in common?
The largest shared holdings are Alkermes Public Limited Company, Xenon Pharmaceuticals Inc, Dianthus Therapeutics Inc, Acadia Pharmaceuticals Inc., Edgewise Therapeutics Inc.
Should I own both IBRN and SBIO?
Their portfolios are mostly different, so owning both can add diversification. Check how each fits your overall allocation.
Which holds more stocks, IBRN or SBIO?
SBIO is broader, with 89 positions versus 78 for IBRN. Overlap here is measured on each fund's top 25 holdings, which carry most of the weight.

Overlap is computed from each fund's top 25 holdings in its latest SEC Form N-PORT filing, with weights normalized to the top 25; for each shared security we count the smaller of the two weights. Educational information, not investment advice.